Insulin-like growth factor-binding protein-2 inhibits proliferation of human embryonic kidney fibroblasts and of ICF-responsive colon carcinoma cell lines

被引:64
作者
Höflich, A
Lahm, H
Blum, W
Kolb, H
Wolf, E
机构
[1] Univ Munich, Lehrstuhl Mol Tierzucht & Haustiergenet, Genzentrum, D-81377 Munich, Germany
[2] Stadt Krankenhaus Munchen Harlaching, Inst Klin Chem, D-81545 Munich, Germany
关键词
insulin-like growth factor binding protein-2; 293; cell; colon carcinoma cell; cell proliferation; growth inhibition;
D O I
10.1016/S0014-5793(98)01011-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
So far, the physiological role of insulin-like growth factor binding protein-2 (IGFBP-2) has not been demonstrated directly. Therefore, we transfected 293 cells with an expression vector containing the CMV promoter and the complete cDNA of mouse IGFBP-2, Secretion of bioactive IGFBP-2 into conditioned medium was demonstrated by Western ligand and Western immunoblotting and quantified by specific RIA, For the analysis of cell proliferation three clones exhibiting either high or low/no IGFBP-2 expression were selected and compared to non-transfected parental 293 cells. IGFBP-2 secreting clones displayed reduced conversion of thiazolyl blue when compared to negative clones or non-transfected parental 293 cells (P < 0.01). The lower growth activity measured in the IGFBP-2 secreting clones was compensated in great part by the administration of exogenous IGF-I or -II. Conditioned media of IGFBP-2 secreting clones inhibited growth of IGF-responsive colon tumor cell lines (LS513, MT-29) while those of negative clones did not. In addition, conditioned medium from a clone expressing high levels of IGFBP-2 inhibited anchorage-independent growth of LS513 and MT-29 cells. In contrast, growth of an IGF-unresponsive tumor cell line (Co-115) was not affected by the conditioned media. We hypothesize that IGFBP-2 might sequester the IGFs and thus prevent them from transferring their mitogenic signals. (C) 1998 Federation of European Biochemical Societies.
引用
收藏
页码:329 / 334
页数:6
相关论文
共 51 条
[1]
INSULIN-LIKE GROWTH FACTOR-I (IGF-I) AND RETINOIC ACID MODULATION OF IGF-BINDING PROTEINS (IGFBPS) - IGFBP-2, IGFBP-3, AND IGFBP-4 GENE-EXPRESSION AND PROTEIN SECRETION IN A BREAST-CANCER CELL-LINE [J].
ADAMO, ML ;
SHAO, ZM ;
LANAU, F ;
CHEN, JC ;
CLEMMONS, DR ;
ROBERTS, CT ;
LEROITH, D ;
FONTANA, JA .
ENDOCRINOLOGY, 1992, 131 (04) :1858-1866
[2]
Binding of insulin-like growth factor (IGF) I or II to IGF-binding protein-2 enables it to bind to heparin and extracellular matrix [J].
Arai, T ;
Busby, W ;
Clemmons, DR .
ENDOCRINOLOGY, 1996, 137 (11) :4571-4575
[3]
BLUM WF, 1993, GROWTH REGULAT, V3, P100
[4]
BOISCLAIR YR, 1994, GROWTH REGULAT, V4, P136
[5]
INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN ENHANCEMENT OF INSULIN-LIKE GROWTH FACTOR-I (IGF-I)-MEDIATED DNA-SYNTHESIS AND IGF-I BINDING IN A HUMAN BREAST-CARCINOMA CELL-LINE [J].
CHEN, JC ;
SHAO, ZM ;
SHEIKH, MS ;
HUSSAIN, A ;
LEROITH, D ;
ROBERTS, CT ;
FONTANA, JA .
JOURNAL OF CELLULAR PHYSIOLOGY, 1994, 158 (01) :69-78
[6]
INSULIN-LIKE GROWTH-FACTOR AXIS ABNORMALITIES IN PROSTATIC STROMAL CELLS FROM PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA [J].
COHEN, P ;
PEEHL, DM ;
BAKER, B ;
LIU, F ;
HINTZ, RL ;
ROSENFELD, RG .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 79 (05) :1410-1415
[7]
GROWTH-STIMULATION BY TRANSFECTION OF INTESTINAL EPITHELIAL-CELLS WITH AN ANTISENSE INSULIN-LIKE GROWTH-FACTOR BINDING PROTEIN-2 CONSTRUCT [J].
CORKINS, MR ;
VANDERHOOF, JA ;
SLENTZ, DH ;
MACDONALD, RG ;
PARK, JHY .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, 211 (03) :707-713
[8]
THE EXPRESSION OF INSULIN-LIKE GROWTH-FACTOR (IGF)-BINDING PROTEIN-2 AND IGF-II GENES IN THE TISSUES OF THE DEVELOPING OVNE FETUS [J].
DELHANTY, PJD ;
HAN, VKM .
ENDOCRINOLOGY, 1993, 132 (01) :41-52
[9]
DROP SLS, 1992, GROWTH REGULAT, V2, P69
[10]
NON-LINEARITY OF COLONY FORMATION BY HUMAN-TUMOR CELLS FROM BIOPSY SAMPLES [J].
ELIASON, JF ;
AAPRO, MS ;
DECREY, D ;
BRINKPETERSEN, M .
BRITISH JOURNAL OF CANCER, 1985, 52 (03) :311-318